Zentalis Pharmaceuticals, Inc. (ZNTL) Income Statement
ZNTL 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsZNTL revenue and net income
ZNTL profit margins
ZNTL growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −101.1% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ZNTL quarterly EPS vs estimates
Zentalis Pharmaceuticals beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.58).
ZNTL income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $67.4M | $0 | $0 | $0 | $0 | $0 | $14,000 |
| Cost of revenue | $739,000 | $1.3M | $1.4M | $1.4M | $544,000 | $160,000 | $111,000 | $0 |
| Gross profit | −$739,000 | $67.4M | −$1.4M | −$1.4M | −$544,000 | −$160,000 | −$111,000 | $14,000 |
| Research & development | $107.3M | $167.8M | $235.2M | $172.7M | $175.6M | $84.9M | $38.4M | $18.9M |
| Sales, general & admin | $37.7M | $87.1M | $60.8M | $54.6M | $40.9M | $33.9M | $8.5M | $4.9M |
| Total operating expenses | $152.8M | $258.6M | $299.5M | $227.3M | $216.5M | $118.8M | $46.8M | $23.8M |
| Operating income | −$152.8M | −$191.2M | −$299.5M | −$227.3M | −$216.5M | −$118.8M | −$46.8M | −$23.8M |
| Interest income | — | — | — | — | — | — | $498,000 | $355,000 |
| Interest expense | — | — | — | $2.6M | $110.0M | $2.2M | $1.2M | $0 |
| Income before taxes | −$136.6M | −$165.7M | −$292.9M | −$237.6M | −$166.4M | −$118.1M | −$46.4M | −$23.4M |
| Income taxes | $442,000 | $177,000 | −$601,000 | −$469,000 | −$297,000 | $444,000 | $15,000 | $4,000 |
| Net income | −$137.1M | −$165.8M | −$292.2M | −$236.8M | −$158.7M | −$117.8M | −$45.7M | −$21.1M |
| EBITDA | −$144.3M | −$186.2M | −$247.6M | −$233.6M | −$207.2M | −$118.6M | −$46.7M | −$23.7M |
| EPS (diluted) | −$1.90 | −$2.27 | −$4.64 | −$4.53 | −$3.78 | −$5.58 | −$1.32 | — |
| Gross margin | — | 100.0% | — | — | — | — | — | 100.0% |
| Operating margin | — | −283.6% | — | — | — | — | — | −169,878.6% |
| Net margin | — | −246.0% | — | — | — | — | — | −150,478.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $26.9M | $0 | $0 | $40.6M | $2.1M | $0 |
| Cost of revenue | — | $151,000 | $157,000 | — | $160,000 | $262,000 | $317,000 | $321,000 | $327,000 | $324,000 | $337,000 | $348,000 |
| Gross profit | — | −$151,000 | −$157,000 | — | −$160,000 | −$262,000 | $26.9M | −$321,000 | −$327,000 | $40.2M | $1.8M | −$348,000 |
| Research & development | $63.9M | $28.7M | $29.5M | $22.9M | $27.6M | $27.2M | $33.0M | $36.8M | $48.4M | $49.6M | $51.6M | $46.8M |
| Sales, general & admin | $18.4M | $9.3M | $7.9M | $10.8M | $7.3M | $10.6M | $40.0M | $14.6M | $17.1M | $16.1M | $16.7M | $16.0M |
| Total operating expenses | $82.2M | $37.7M | $37.4M | $33.7M | $36.1M | $45.6M | $76.7M | $51.4M | $65.1M | $65.0M | $67.9M | $62.7M |
| Operating income | −$82.2M | −$37.9M | −$37.4M | −$33.7M | −$36.1M | −$45.6M | −$49.8M | −$51.4M | −$65.1M | −$24.8M | −$67.9M | −$62.7M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $6.0M | — |
| Income before taxes | −$77.4M | −$35.2M | −$34.8M | −$26.7M | −$26.9M | −$48.3M | −$47.7M | −$40.2M | −$88.0M | $10.2M | −$61.1M | −$55.5M |
| Income taxes | $258,000 | $120,000 | $442,000 | — | — | — | −$205,000 | −$27,000 | $266,000 | $143,000 | −$135,000 | $31,000 |
| Net income | −$77.6M | −$35.4M | −$35.2M | −$26.7M | −$26.9M | −$48.3M | −$47.5M | −$40.2M | −$88.3M | $10.1M | −$60.9M | −$55.5M |
| EBITDA | −$77.2M | −$35.1M | −$34.6M | −$26.5M | −$34.7M | −$37.6M | −$45.8M | −$39.9M | −$87.7M | $10.5M | −$60.7M | −$55.2M |
| EPS (diluted) | −$0.59 | −$0.50 | −$0.49 | −$0.37 | −$0.37 | −$0.67 | −$0.61 | −$0.56 | −$1.24 | $0.14 | −$0.93 | −$0.79 |
| Gross margin | — | — | — | — | — | — | 100.0% | — | — | 99.2% | 84.0% | — |
| Operating margin | — | — | — | — | — | — | −185.6% | — | — | −61.1% | −3,228.2% | — |
| Net margin | — | — | — | — | — | — | −176.7% | — | — | 24.8% | −2,895.3% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ZNTL's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ZNTL financial results
Zentalis Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $137.1 million. Diluted earnings per share came to −$1.90.
See the ZNTL stock overview for the latest quote and news, or the ZNTL chart for price history and technical indicators.
ZNTL income statement FAQ
Does Zentalis Pharmaceuticals have revenue?
Zentalis Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Zentalis Pharmaceuticals profitable?
No. Zentalis Pharmaceuticals reported a net loss of $137.1 million in fiscal 2025.
How much does Zentalis Pharmaceuticals spend on research and development?
Zentalis Pharmaceuticals spent $107.3 million on research and development in fiscal 2025.
What are Zentalis Pharmaceuticals's earnings per share?
Zentalis Pharmaceuticals earned $-1.90 per diluted share in fiscal 2025, compared with $-2.27 a year earlier.
When will Zentalis Pharmaceuticals report its next earnings?
Zentalis Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Zentalis Pharmaceuticals's fiscal year end?
Zentalis Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.